Welcome to our dedicated page for Goodrx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoodRx Holdings, Inc. filings document the financial reporting, governance, and public-company controls of a Nasdaq-listed digital healthcare platform for prescription savings. Its 8-K reports furnish quarterly operating results, revenue categories such as prescription transactions, subscriptions, and Pharma Direct, non-GAAP financial measures, and business outlook disclosures tied to medication access and pharmacy-market conditions.
GoodRx regulatory filings also cover proxy governance, board classification matters, director departures, officer appointments and resignations, executive compensation, equity awards under the 2020 Incentive Award Plan, and changes in the company’s independent registered public accounting firm.
On 08/08/2025 Nabiey Romin, Chief Accounting Officer of GoodRx Holdings, Inc. (GDRX), reported the vesting of 12,663 restricted stock units (RSUs) and a disposition of 4,531 Class A common shares at a price of $3.47 per share. The Form 4 is signed by Gracye Cheng, Attorney-in-Fact, dated 08/08/2025.
The filing shows beneficial ownership following these transactions of 134,207 Class A shares (direct) and 88,639 derivative securities reported as direct holdings. The RSU disclosure states each unit equals one share, with 6.25% vested on August 8, 2023 and the remaining 93.75% vesting in equal quarterly installments over 15 quarters.
Spectrum Equity reduces, but still retains a significant position in GoodRx Holdings, Inc. (NASDAQ: GDRX) according to Amendment No. 6 to its Schedule 13D. The filing reflects events through 2 July 2025 and amends the original Schedule 13D first filed in June 2021 and most recently updated in June 2025.
Key ownership data: the five affiliated reporting entities — Spectrum Equity VII, L.P.; Spectrum Equity Associates VII, L.P.; Spectrum VII Investment Managers’ Fund, L.P.; Spectrum VII Co-Investment Fund, L.P.; and SEA VII Management, LLC — now beneficially own an aggregate 14,905,133 Class A shares, equal to 12.9 % of the outstanding Class A common stock (115,205,298 shares assumed outstanding). The bulk of the holding (14,865,346 shares) resides in Spectrum Equity VII, L.P., with two smaller funds owning 25,445 and 14,342 shares, respectively.
Recent transactions:
- Pro-rata distribution: On 2 July 2025, Spectrum Equity VII, L.P. distributed 3,989,323 Class A shares of GoodRx to its limited partners for no consideration (the “July 2025 Distribution”).
- Follow-on sales: After the distribution, Spectrum VII Co-Investment Fund, L.P. and Spectrum VII Investment Managers’ Fund, L.P. sold a combined 10,677 Class A shares in the open market, generating net proceeds of $50,606.46.
Control structure: SEA VII Management, LLC is the general partner of the other Spectrum vehicles and, together with eight named individuals, shares voting and dispositive power over the reported shares. Each individual disclaims beneficial ownership.
Implications for investors: The 3.99 million-share distribution lowers Spectrum Equity’s direct stake while increasing GoodRx’s public float, potentially improving liquidity but signalling a partial exit by an early sponsor. Despite the reduction, Spectrum Equity remains a >10 % beneficial owner, so it continues to be a significant shareholder with aligned interests, although further sell-downs remain possible. No other material changes, litigation matters or additional share transactions were reported in the past 60 days.